Mike Hennessy Jr, president and CEO, MJH Life Sciences®
Oncology clinical trials have always been a unique area in the R&D landscape. One of their greatest and longest-standing challenges has been enrollment. The number of patients participating in clinical studies for cancer, when compared to overall levels, has always been heavily lopsided to the low end—and even further so when you measure minority patient populations specifically. However, change could be on the way. According to a recent study published by the Journal of Clinical Oncology, which reviewed data from the 1,200 Commission on Cancer programs, the overall estimated patient participation rate in cancer treatment trials was 7.1% during the period 2013-2017, which was higher than historical estimates of <5%.
While the improvement seems marginal, what are some of the advancements moving the needle in perhaps expanding the pool of potential participants in oncology studies? To that end, our May issue of Applied Clinical Trials examines what the future landscape of oncology R&D could look like.
Leading off our coverage is a look at the scientific advances and emerging modalities that are pacing drug development efforts in cancer. Following that is an article on harnessing the potential of kinase inhibitors (KIs) for future advances in cancer. According to the authors, more than 50 KIs have been approved by the FDA to treat 20 types of cancer. Notably, with KIs, physiologically-based pharmacokinetic modeling is used for first-in-human pharmacokinetic predictions early in the discovery process, and for informing inclusion/exclusion criteria for the clinical trial protocol. This model can be employed if a sponsor is considering combining its KI drug candidate with another small molecule, to manage comedications, and create virtual cancer patient populations to evaluate compounds.
Wrapping up our May feature articles is an overview of the FDA’s recently released guidance in support of Project Optimus, which is a dosing-reform program established by the agency’s Oncology Center of Excellence. Since the FDA announced the initiative in 2021, the industry has responded with a wave of technological advancements, especially driven by artificial intelligence. With Project Optimus, the authors note that the FDA has taken a clear position of shifting away from traditional chemotherapy and promoting more progressive tailored approaches.
Again, while recent increases in cancer trial enrollment seem minimal at the moment, with the innovations showcased in this issue of ACT (also check out our “In Focus” dive into the complex playing field for oncology trials), plus the many more out there, I am confident the industry is on the right path toward bringing cancer patients life-changing therapies faster and more efficiently than ever before.
As always, thank you for reading.
Mike Hennessy Jr is president and CEO of MJH Life Sciences®
